Tenascin Patterns of Expression in Duct Carcinoma In Situ of the Breast
|
|
- Lee Roberts
- 5 years ago
- Views:
Transcription
1 266 Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 Tenascin Patterns of Expression in Duct Carcinoma In Situ of the Breast Basem F. Iskaros, Cristina P. Sison, and Steven I. Hajdu Department of Pathology, North Shore University Hospital, Manhasset, New York Abstract. Immunohistochemical methods were used to study tenascin (TN) expression in duct carcinoma in situ (DCIS) of the breast of different histologic types. We evaluated 82 lumpectomy specimens of DCIS. There were 5 cases of comedo type, 19 cases of noncomedo type, and 58 cases of mixed comedo and noncomedo type. In 44 cases, the intraductal carcinomas were associated with infiltrating (invasive) duct carcinoma. TN expression was studied by immunohistochemical methods using monoclonal mouse anti-human tenascin (DAKO- TN2M636;1:50 dilution). Positivity was recorded on a scale of 0 to 2+ for presence of TN staining around tumor ducts and thickness of TN-stained fibrous bands. TN showed positive correlation between thick bands around comedo DCIS and thin bands around noncomedo DCIS. The TN score had statistically significant positive association with high nuclear grade (p 0.004), periductal inflammatory infiltrate of DCIS (p ), associated extensive central necrosis of DCIS (p ), and comedo DCIS (p ). TN expression in the stroma was positively associated with tumor size (p ), extensive central necrosis (p 0.02), comedo DCIS (p ), and associated invasive carcinoma (p 0.006). The TN score did not correlate with duct size, multicentric carcinoma, or associated microcalcification. These results demonstrate the different biological nature of DCIS comedo type and suggest its preinvasive potential. Keywords: tenascin, breast carcinoma, duct carcinoma in situ, extracellular matrix, adhesion glycoprotein Introduction Tenascin (TN) is a glycoprotein component of the extracellular matrix (ECM). It is generally expressed at sites of epithelial-mesenchymal interactions during fetal development, and at the epithelial tumor-stromal interface of various benign and malignant epithelial tumors [1,2]. Early investigations on experimentally induced rare breast tumors detected TN in the stroma of malignant tumors but not in that of benign tumors. Thus T N was regarded as a stromal marker of epithelial malignancy [3]. Later, TN was noted in the normal and hyperplastic adult breast as thin bands in the periductal stromal region. In fibroadenomas and carcinoma in situ, TN expression is increased, forming thick periductal bands. In invasive breast Address correspondence to Steven I. Hajdu, M.D., Department o f Pathology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA; tel: , fax: carcinoma, TN expression is markedly increased in the stroma around infiltrating tumor cells [4,5]. It is evident that pathologic hyperplasias of the breast are characterized not only by cellular alterations but also by demonstrable quantitative and qualitative changes of the ECM. Moreover, evidence has shown that ECM proteins may modify gene expression and may serve as vehicles for cytokine-mediated signals of intercellular communication [6]. Duct carcinoma in situ (DCIS) has become clinically important since the advent of routine, high quality mammography [7,8]. Older series recorded an incidence of 1 % to 5% of DCIS [9]. Recent studies have shown that approximately 15 to 25% of mammographically screened patients have this type of early breast carcinoma [10,11]. This increase in detection provides a great opportunity to identify patients who are at risk for invasive breast cancer. Knowledge of the biologic potential of such lesions has an important impact on patient management and treatment options. Lagios et al [12], in 1989, were /00/ $1.50; 2000 by the Association of Clinical Scientists, Inc.
2 Tenascin expression and breast carcinoma 267 the first to suggest a relationship between histological features and the risk of local recurrence in patients with DCIS treated with less than mastectomy [12]. It was demonstrated that comedo DCIS represents a high nuclear grade subtype that carries an increased risk of both recurrent DCIS and progression to invasive mammary carcinoma [13,14]. By exclusion, the term noncomedo DCIS has come to refer to all other forms of DCIS. To understand the changes of the ECM proteins in DCIS, we used immunohistochemical methods with archival tissue sections of formalin-fixed, paraffin-embedded surgical materials. In this study, we demonstrated different patterns of expression of the ECM protein, TN, in comedo and noncomedo DCIS, and correlated the patterns of TN expression with the biologic behavior of DCIS. Materials and M ethods The pathology records of 82 patients with DCIS were retrieved from the files of North Shore University Hospital. Hematoxylin- and eosin-stained slides from all included cases were reviewed by two of the authors. These cases reflected a spectrum of DCIS including the pure comedo type. We randomly included DCIS cases associated with infiltrating (invasive) carcinoma of the breast. The biopsy specimens were categorized histopathologically, as shown in Table 1, by tumor variables including (1) histologic pattern of DCIS, (2) Table 1. Tumor characteristics in 82 cases of duct carcinoma in situ of the breast Parameter or characteristic Mean value % or no. of cases Tumor diameter (mm, mean ± SD) 13.3 ± 7.7 Duct diameter (mm, mean ± SD) 2.2 ± 1.4 Pure comedo type 5 6% Mixed type 58 70% Noncomedo type 19 23% Associated invasive carcinoma 44 54% Associated extensive central necrosis 50 61% Associated periductal inflammation 48 58% Associated microcalcification 62 76% Positive margin of excision 46 56% Multicentric tumors 33 40% extensive central necrosis (estimated as >50% of tumor duct lumen), (3) tumor size, (4) unicentric versus multicentric lesion, (5) presence of microcalcification, (6) associated invasive carcinoma, (7) positive margins of excision, and (8) associated inflammation. TN expression was detected by immunohistochemical methods as previously reported [15]. For immunostaining, all blocks were cut into 5- im sections and placed on lysine-coated glass slides. The sections were deparaffinized in xylene and rehydrated with a graded ethanol series (100% to 70%), then rinsed in water, incubated in 3% hydrogen peroxide for 20 min, washed in tap water, and pretreated with pro tease (1:100) in phosphate-buffered saline (PBS) for 30 min at room temperature. The slides were rinsed in tap water, distilled water, and PBS. The monoclonal antihuman mouse tenascin antibody (DAKO, Carpinteria, CA.,TN2M 636;l/50 dilution) was added and incubated for 4r h in a humidified chamber. Slides were washed in PBS and biotinylated antimouse antibody was added for 15 min. After an additional PBS wash, the slides were treated with 3,3- diaminobenzidine (DAKO, Carpinteria, CA) for 5 min. Slides were counterstained with hematoxylin, dehydrated, and mounted with glass coverslips. TN positivity in the periductal region was graded from 0 to 2+ as follows: 0, no staining; 1 +, stained periductal thin band (<4 im by ocular micrometer); 2+, stained periductal thick band (>3 (Jm). T N positivity in surrounding stroma was recorded as 0 when absent and 1 + when present. The relationships between TN score and the abovementioned histopathologic tumor variables were analyzed using Fishers exact test. P-values, based on a two-tailed test, were regarded as significant at less than Pairwise comparisons by Fishers exact test with Bonferroni s correction were carried out as needed. Results Expression of TN in 82 cases of DCIS of the breast was studied by immunohistochemistry and graded on a scale from 0 to 2+. Expression oftn was found as a thin band around hyperplastic ducts and DCIS of the breast, noncomedo type (Fig. 1). In DCIS, comedo type, TN expression was seen as thick bands around the tumor ducts (Fig. 2). In tumors associated with
3 268 Annals o f Clinical & Laboratory Science Fig. 1. Tenascin expression showing periductal staining form ing th in bands around duct carcinoma in situ, noncomedo type (xloo). Fig. 2. Tenascin expression showing periductal staining forming thick bands around duct carcinoma in situ, comedo type (xloo). m icroinvasion or frankly invasive carcinoma, T N expression was found in the tumor stroma surrounding the invading tumor cells. The p-values obtained by Fisher s exact test for each o f the tumor-associated variables are given in Table 2. There was significant association between the three levels o f nuclear grade and T N bands around tumor ducts. In the nuclear grade 3 group, 67% (26/39) had thick T N bands around the ducts and 33% (14/42) had thin T N bands. In the nuclear grade 2 group, 33% (13/39) had thick T N bands and 60% (25/42) had thin T N bands. In the nuclear grade 1 group, none had thick T N bands and 7% (3/42) had thin T N bands around tumor ducts. A higher nuclear grade was associated with thick T N bands around tumor d u cts. P airw ise c o m p a r iso n s sh o w ed that the proportion o f tumors with thick T N bands differed significantly between grades 2 and 3 (p <0.012). There was significant association between com edo type DCIS and thickness o f the T N bands around tumor ducts. Am ong the pure comedo type o f tumor, there were 10% (4/39) with thick T N bands and 2% (1/42) with thin bands. Am ong the mixed type o f tumor, there were 85% (33/39) with thick T N bands and 60% (25/42) with th in T N bands. A m ong other types o f tumors, there were 5% (2/39) with thick T N bands and 38% (16/42) with th in T N bands. Pairwise comparisons showed that the proportion o f tumors with thick bands was significantly different between the pure comedo and others (p<0.008) and between mixed type and others (p<0.0008). There was no difference in the proportion o f tumors with thick T N bands around tumor ducts between pure comedo and mixed type (p 0.39).
4 Tenascin expression and breast carcinoma 269 Table 2. Tenascin (TH) expression around tumor ducts and in the tumor stroma, in relation to variables associated with duct carcinoma in situ of the breast Variable or characteristic TN around tumor ducts TN in tumor stroma thick band (total N=39) thin band (total N=42) P present absent (total N=31) (total N=51) P Tumor diameter (mm, mean ± SD) ± ± ± ± Nuclear grade (%, N) grade 1 grade 2 grade 3 0% (0) 33.3% (13) 66.7% (26) 7.1% (3) 59.5% (25) 33.3% (14) % (0) 45.2% (14) 54.8% (17) 7.8% (4) 47.1% (24) 45.1% (23) 0.31 Comedo type (%, N) pure comedo mixed others 10.3% (4) 84.6% (33) 5.1% (2) 2.4% (1) 59.5% (25) 38.1% (16) % (1) 93.5% (29) 3.2% (1) 7.8% (4) 56.9% (29) 35.3% (18) Associated invasive carcinoma % positive (N) 56.4% (22) 52.4% (22) % (23) 41.2% (21) Associated extensive central % positive (N) necrosis 82.1% (32) 42.9% (18) % (24) 51.0% (26) 0.02 Associated inflammation % positive (N) 79.5% (31) 40.5% (17) % (21) 52.9% (27) 0.25 Associated microcalcification % positive (N) 74.4% (29) 76.2% (32) % (22) 78.4% (40) 0.60 Margin of excision % positive (N) 58.1% (18) 54.9% (28) 0.82 Multicentric tumors % multicentric (N) 38.5% (15) 42.9% (18) % (11) 43.1% (22) 0.64 Tumor diameter % large (> 20 mm) (N) 25.6% (10) 19.0% (8) % (15) 5.9% (3) There was significant association between inflammation and thickness of thetn band around the ducts. Among the inflamed tumors, 80% (31/39) had thick TN bands around the tumor ducts and 41% (17/42) had thin TN bands around the tumor ducts. Among the non-inflamed tumors, 21% (8/39) had thick TN bands around the tumor ducts and 60% (25/42) had thin TN bands. There was significant association between extensive central necrosis and the thickness oft N bands around tumor ducts. Among tumors with extensive central necrosis, 82% (32/39) had thick TN bands around tumor ducts, versus 43% (18/42) with thin bands. Among tumors negative for extensive necrosis, only 18% (7/39) had thick TN bands, as opposed to 57% (24/42) with thin TN bands.
5 270 Annals o f Clinical & Laboratory Science There were no significant associations between the thickness of the TN bands around tumor ducts and microcalcification, associated invasion, positive margins of exclusion, multicentricity, or tumor size. There was significant association between the presence of associated invasion and expression of TN in the stroma. Among tumors with associated invasion, 74% (23/31) showed TN expression in the stroma and 41% (21/51) did not. Among those without associated invasion, 26% (8/31) showed TN expression in the stroma while 59% (30/51) did not. There was significant association between comedo type DCIS and the expression of TN in the stroma. Among the pure comedo type of tumors, there were only 3% (1/31) positive fortn in the stroma and 8% (4/51) negative for TN in the stroma. Among the mixed type of tumors, there were 94% (29/31) positive fort N in the stroma and 57% (29/51) negative for TN in the stroma. Among the other types of tumors, there were 3% (1/31) positive fort N and 35% (18/ 51) negative fort N in the stroma. Pairwise comparisons showed that presence of TN in the stroma was significantly different between the mixed type and others (p ). There was no significant difference in the proportion of tumors with TN in the stroma between the pure comedo and mixed types (p 0.357) or between pure comedo and other types (p 0.380). There was significant association between extensive central necrosis and the expression oftn in the stroma. Among those tumors associated with extensive central necrosis, 77% (24/31) were positive for TN in the stroma and 51% (26/51) were negative fortn in the stroma. Among those tumors without extensive necrosis, 23% (7/31) were positive for T N in the stroma while 49% (25/51) were negative. Large tumors (ie, tumors with diameter >20 mm) tended to express TN in the stroma more often than small tumors (ie, tumors with diameter <20 mm). There were no significant associations between the presence of TN in the tumor stroma and the three levels of nuclear grade, inflammation, microcalcification, positive margin of excision, or multicentricity. Discussion DCIS has traditionally been viewed as one entity, but recent studies suggest that, like invasive carcinoma, DCIS represents a heterogeneous group of lesions [16,17]. In the late 1980s, several groups began to suggest that there were biologic differences between fully developed comedo DCIS and other DCIS variants. Some authors have presented data to show that comedo DCIS is more likely to be associated with occult invasion and multicentricity [13,14]. Also, it has been proposed that noncomedo DCIS with necrosis is an intermediate lesion between noncomedo and comedo DCIS [14,18]. In our study, 71% of all randomly selected DCIS cases were mixed comedo and noncomedo DCIS. This observation demonstrates the known heterogeneity of this disease and also suggests progression of noncom edo DCIS to the more aggressive comedo type. In the normal human breast, TN expression, as visualized by immunohistochemistry, is reported to be a constant ECM component throughout life, although there is markedly increased expression in carcinogenesis and malignant growth. Derangements of cell-cell adhesion, together with a change of ECM protein turnover, are critical events in tumor progression and are involved in invasion. The role of TN in tumor invasion and metastasis is poorly understood. The relationship between TN expression and prognosis in malignant tumors is controversial [ 19-21]. TN synthesis is induced in the stroma as a result of interaction with the neoplastic epithelium. Transforming growth factor beta is a regulatory protein that is reported to stimulate the production oftn [22,23]. Recently, we reported the patterns o ft N expression and their correlation with established prognostic factors of invasive breast carcinoma [15]. In this study, we demonstrated different patterns oftn expression in comedo and noncomedo DCIS. Also, we found direct correlation between TN expression in the stroma of DCIS and tumor size, extensive central necrosis, comedo DCIS, and DCIS associated with invasion. These findings demonstrate the biologic difference between comedo and non-comedo DCIS, and support previous studies that showed high incidence of invasion associated with comedo DCIS [13,14]. They also support the known biologic difference of comedo DCIS and its preinvasive potential. Although there are reports of association of multicentric lesions with comedo DCIS and invasive carcinoma [15,4,25], our results did not show correlation between TN expression and m ulticentricity. T he im plications o f the
6 Tenascin expression and breast carcinoma 271 multicentricity of DCIS are unclear. Presence of extensive central necrosis in noncomedo DCIS was found to have a pattern oftn expression around tumor ducts and in the tumor stroma similar to that in the comedo type DCIS (Table 2). This observation strongly supports the existence of variants, such as an aggressive form of noncomedo type or an intermediate lesion between noncomedo and comedo DCIS. A cknow ledgem ents. We thank Ms. Eleanore Boss and Ms. Lisa Moskowitz for skillful technical assistance, and Ms. Mei L. Wu for excellent secretarial assistance. References 1. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Ann Rev Cell Biol 1998;5: Erickson HP, Lightner VA. Hexabrachion protein (tenascin, cytotactin, brachionectin) in connective tissues, embryonic brain and tumors. Adv Cell Biol 1988;2: Mackie EJ, Chiquet-Ehrisman R, Pearson CA, et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc N atl Acad Sci USA 1987;84: HoweedyAA, Virtanen I, LaitinenL, etal. Differential distribution of tenascin in the normal, hyperplastic and neoplastic breast. Lab Invest 1990;63: Gould VE, Koukoulis GK, Virtanen I. Extra-cellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Diff Dev 1990;32: Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991;113: Lagios MD. Human breast precancer: cancer status. Cancer Surv 1993;2: Margolin FR, Lagios MD. Mammographic detection of early breast cancer: ten years experience in a community hospital. West J Med 1986;144: Rosner D, Bedwani RN, Vana J, et al. Non-invasive breast carcinoma: results of a national survey of the American College of Surgeons. Ann Surg 1980; 192: Schnitt SJ, Silen N, Sadowsky NL, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 1988;318: Schwartz GF, Feig SA, Patchefsky AS. Significance and staging of nonpalpable carcinomas of the breast. Surg Gynecol Obstet 1988;166: Lagios M D, M argolin FR, W estdahl PR, et al. Mammographically detected duct carcinoma in situ. Cancer 1989;63: PageDL, Steel CM, Dixon JM. ABC of breast diseases. Carcinoma in situ and patients at high risk of breast cancer. Brit Med J 1995;310: Silverstein MJ, Cohlan BG, Gierson ED, et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 1992;28: Iskaros BF, Hu X, Sparano JA, Fineberg SA. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J Surg Oncol 1998;68: Patchefsky AS, Schwartz FG, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63: Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994;73: Scott MA, Lagios M D, Axelsson K, et al. Duct carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol 1997;28: Moch H, Torhost J, Durmuller U, et al. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathol Res Pract 1993;189: Shoji T, Kamiya T, Tsubura A, et al. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res 1993;55: Iskaros BF, Tanaka KE, H u X, et al. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. J Surg Oncol 1997;64: Walker RA, Dearing SJ, Gallacher B. Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Brit J Cancer 1994;69: C hiquet-e hrism an R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 1994;49: Lagios MD, Westdahl PR, Margolin FR, et al. Duct carcinom a in situ. R elationship o f extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastasis, and short-term treatment failure. Cancer 1982;50: Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999;85:
Tenascin (TN) is a large glycoprotein of the extracellular
Tenascin Expression in Intraepithelial Neoplasia and Invasive of the Uterine Cervix Basem F. Iskaros, MD; Leopold G. Koss, MD Tenascin (TN) is a large glycoprotein of the extracellular matrix that is transiently
More informationUltrastructure of the Periductal Area of Comedo Carcinoma in situ of the Breast
284 Annals of Clinical & Laboratory Science, vol. 31, no. 3, 2001 Ultrastructure of the Periductal Area of Comedo Carcinoma in situ of the Breast Ping Tang, Saul Teichberg, Beth Roberts, and Steven I.
More informationA712(18)- Test slide, Breast cancer tissues with corresponding normal tissues
A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding
More informationRecurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction Aldona J. Spiegel, M.D., and Charles E. Butler, M.D. Houston, Texas Skin-sparing
More informationA712(19)- Test slide, Breast cancer tissues with corresponding normal tissues
A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding
More informationInt. J. Curr. Res. Med. Sci. (2018). 4(7): 1-7. International Journal of Current Research in Medical Sciences
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Original Research Article Volume 4, Issue 7-2018 DOI: http://dx.doi.org/10.22192/ijcrms.2018.04.07.001
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationManagement of Ductal Carcinoma In Situ
Management of Ductal Carcinoma In Situ Stella Hetelekidis, MD Stuart J. Schnitt, MD Monica Morrow, MD Jay R. Harris, MD Introduction Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma,
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationBREAST PATHOLOGY. Fibrocystic Changes
BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationCytyc Corporation - Case Presentation Archive - March 2002
FirstCyte Ductal Lavage History: 68 Year Old Female Gail Index: Unknown Clinical History: Negative Mammogram in 1995 6 yrs. later presents with bloody nipple discharge Subsequent suspicious mammogram Suspicious
More informationComparison of CD10 expression in stroma of epithelial and mesenchymal tumors of the breast
Global Advanced Research Journal of Medicine and Medical Science (ISSN: 2315-5159) Vol. 4(1) pp. 051-056, January, 2015 Available online http://garj.org/garjmms/index.htm Copyright 2015 Global Advanced
More informationInvasive Papillary Breast Carcinoma
410 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More informationMammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand
Mammographic imaging of nonpalpable breast lesions Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand Introduction Contents Mammographic signs of nonpalpable breast cancer
More informationPatterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma
Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma Hadia. Mohammed. Abdalla. Abdalrhman *, Elsadig.A.Adam, Ayda.D.A.Allatif 3,'Namareg.E.Afadul
More informationInterpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
More informationPromise of a beautiful day
Promise of a beautiful day Ductal carcinoma in Situ Lobular Carcinoma in Situ Natural History Manosmed Tartous Oct 2009 Gérard ABADJIAN MD Pathology Department Hôtel-Dieu de France. Associate Professor
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationHow to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
Global Breast Cancer Conference 2016 & 5 th International Breast Cancer Symposium April 29 th 2016, 09:40-10:50 How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationEpithelial Columnar Breast Lesions: Histopathology and Molecular Markers
29th Annual International Conference Advances in the Application of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells 25 th -27t h June, 2012, Mykonos, Greece Epithelial Columnar
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationBreast Pathology. Breast Development
Breast Pathology Lecturer: Hanina Hibshoosh, M.D. Reading: Kumar, Cotran, Robbins, Basic Pathology, 6th Edition, pages 623-635 Breast Development 5th week - thickening of the epidermis - milk line 5th
More informationIMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA
& IMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA Suada Kuskunović*, Svjetlana Radović, Mirsad Dorić, Ajna Hukić, Mirsad Babić, Ivana Tomić,
More informationANATOMIC PATHOLOGY. Original Article
ANATOMIC PATHOLOGY Original Article Intraductal Carcinoma Associated With Invasive Carcinoma of the Breast A Comparison of the Two Lesions With Implications for Intraductal Carcinoma Classification Systems
More informationBreast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens
Breast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens M. Shahid Siddiqui,Naila Kayani,Sara Sulaiman,Akbar S. Hussainy,Sajid H. Shah,Suhail Muzaffar ( Faculty of Health Sciences,
More informationDuctal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA
Ductal Carcinoma in Situ Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Definition of DCIS WHO 2012 A neoplastic proliferation
More informationPapillary Lesions of the Breast
Papillary Lesions of the Breast Laura C. Collins, M.D. Associate Professor of Pathology Associate Director, Division of Anatomic Pathology Beth Israel Deaconess Medical Center and Harvard Medical School
More informationPapillary Lesions of the Breast: WHO Update
Papillary Lesions of the Breast: WHO Update Stuart J. Schnitt, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Papillary Lesions of the Breast
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationDuctal carcinoma in situ
Breast series CLINICAL PRACTICE Ductal carcinoma in situ Management update Kirsty Stuart, BSc (Med), MBBS, FRANZCR, is a radiation oncologist, NSW Breast Cancer Institute, Westmead Hospital, New South
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationSenior of Histopathology Department at Khartoum, Radiation and Isotopes Center
EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 2/ May 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Immune Histochemical Evaluation of AMACR (P504S) in Prostatic Adenocarcinoma
More information04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA
Intraductal Papillary Neoplasms Of Breast Savitri Krishnamurthy MD Professor of Pathology Deputy Division Head The University of Texas MD Anderson Cancer Center 25 th Annual Seminar in Pathology Pittsburgh,
More informationRSNA, /radiol Appendix E1. Methods
RSNA, 2016 10.1148/radiol.2016151097 Appendix E1 Methods US and Near-infrared Data Acquisition Four optical wavelengths (740 nm, 780 nm, 808 nm, and 830 nm) were used to sequentially deliver the light
More informationDiseases of the breast (1 of 2)
Diseases of the breast (1 of 2) Introduction A histology introduction Normal ducts and lobules of the breast are lined by two layers of cells a layer of luminal cells overlying a second layer of myoepithelial
More informationDuctal Carcinoma In Situ of the Breast: Controversial Issues
Ductal Carcinoma In Situ of the Breast: Controversial Issues MELVIN J. SILVERSTEIN The Breast Center*, Van Nuys, California, USA Key Words. DCIS Ductal carcinoma in situ Noninvasive breast cancer Intraductal
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationLOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE
: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer
More informationLYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR
BREAST LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR HISTOLOGY LOBE: (10 in whole breast) LOBULE: (many per lobe) ACINUS/I, aka ALVEOLUS/I: (many per lobule) DUCT(S): INTRA- or
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationTHE INFLUENCE OF MARGIN WIDTH ON LOCAL CONTROL OF DUCTAL CARCINOMA IN SITU OF THE BREAST
THE INFLUENCE OF MARGIN WIDTH ON LOCAL CONTROL OF DUCTAL CARCINOMA IN SITU OF THE BREAST MELVIN J. SILVERSTEIN, M.D., MICHAEL D. LAGIOS, M.D., SUSAN GROSHEN, H.D., JAMES R. WAISMAN, M.D., BERNARD S. LEWINSKY,
More informationHistopathological Spectrum of Neoplastic and Non-neoplastic Breast Lesions: A Two Years Study
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/69 Histopathological Spectrum of Neoplastic and Non-neoplastic Breast Lesions: A Two Years Study Moolamalla Manasa
More informationIn Situ Breast Carcinoma. James L. Connolly, M.D Beth Israel Deaconess Medical Center Professor of Pathology Harvard Medical School Boston, MA
In Situ Breast Carcinoma James L. Connolly, M.D Beth Israel Deaconess Medical Center Professor of Pathology Harvard Medical School Boston, MA Content In Situ Ductal Carcinoma In Situ Lobular Carcinoma
More informationUniversity Journal of Pre and Para Clinical Sciences
ISSN 2455 2879 Volume 2 Issue 1 2016 Metaplastic carcinoma breast a rare case report Abstract : Metaplastic carcinoma of the breast is a rare malignancy with two distinct cell lines described as a breast
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationOriginal Article. Spontaneous Healing of Breast Cancer
Breast Cancer Vol. 12 No. 2 April 2005 Original Article Rie Horii 1, 3, Futoshi Akiyama 1, Fujio Kasumi 2, Morio Koike 3, and Goi Sakamoto 1 1 Department of Breast Pathology, the Cancer Institute of the
More informationApocrine Mammary Carcinoma
Apocrine Mammary Carcinoma A Clinicopathologic Study of 72 Cases ANDREA D. ABATI, M.D., MAREK KIMMEL, PH.D., AND PAUL P. ROSEN, M.D. Apocrine carcinoma (AC) is an uncommon, poorly characterized type of
More informationHISTOMORPHOLOGICAL SPECTRUM OF BREAST LESIONS
HISTOMORPHOLOGICAL SPECTRUM OF BREAST LESIONS Kiran H. S, Jayaprakash Shetty, Chandrika Rao Assistant Professor, Department of Pathology, Yenepoya Medical College, Mangalore. Professor, Department of Pathology,
More informationMousa. Israa Ayed. Abdullah AlZibdeh. 0 P a g e
1 Mousa Israa Ayed Abdullah AlZibdeh 0 P a g e Breast pathology The basic histological units of the breast are called lobules, which are composed of glandular epithelial cells (luminal cells) resting on
More informationDuctal Carcinoma In Situ of the Breast
2123 Ductal Carcinoma In Situ of the Breast Histologic Categorization and Its Relationship to Ploidy and Immunohistochemical Expression of Hormone Receptors, p53, and c-erbb-2 Protein ConceigZo B. Leal,
More informationMultiple Fibroadenomas Harboring Carcinoma in Situ in a Woman with a Familty History of Breast/ Ovarian Cancer
Multiple Fibroadenomas Harboring Carcinoma in Situ in a Woman with a Familty History of Breast/ Ovarian Cancer A Kuijper SS Preisler-Adams FD Rahusen JJP Gille E van der Wall PJ van Diest J Clin Pathol
More informationTreatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea
Treatment options for the precancerous Atypical Breast lesions Prof. YOUNG-JIN SUH The Catholic University of Korea Not so benign lesions? Imaging abnormalities(10% recall) lead to diagnostic evaluation,
More informationContents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
More informationCLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES
Papillomas. Papillomas are composed of multiple branching fibrovascular cores, each having a connective tissue axis lined by luminal and myoepithelial cells ( Fig. 23-11 ). Growth occurs within a dilated
More informationEvaluation of Breast Specimens Removed by Needle Localization Technique
Evaluation of Breast Specimens Removed by Needle Localization Technique Specimen Handling: The breast specimen when received should be measured and grossly inspected for any orientation designated by the
More informationDisclosure of Relevant Financial Relationships. Breast Pathology Evening Specialty Conference Case #4. Clinical Case: Pathologic Features
Breast Pathology Evening Specialty Conference Case #4 K.P. Siziopikou, MD, PhD Professor of Pathology Director of Breast Pathology and Breast Pathology Fellowship Program Northwestern University Feinberg
More informationCOMPANION MEETING BREAST. Auditorium 11:15 1:00 am. Convenor: A/Professor Gelareh Farshid, SA Pathology, SA
Australasian Division of the International Academy of Pathology Limited ABN 73 008 593 815 36 TH Annual Scientific Meeting Darling Harbour Convention Centre, Sydney, Australia June 3-5, 2011 COMPANION
More informationRegressive Change in High-Grade Ductal Carcinoma In Situ of the Breast. Jason K. Wasserman, MD, PhD, and Carlos Parra-Herran, MD, FCAP
AJCP / Original Article Regressive Change in High-Grade Ductal Carcinoma In Situ of the Breast Histopathologic Spectrum and Biologic Importance Jason K. Wasserman, MD, PhD, and Carlos Parra-Herran, MD,
More informationProtocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Version: BreastInvasive 1.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of
More information6/3/2010. Outline of Talk. Lobular Breast Cancer: Definition of lobular differentiation. Common Problems in Diagnosing LCIS in Core Biopsies
Outline of Talk Lobular Breast Cancer: Common Problems in Diagnosing LCIS in Core Biopsies Definition of lobular differentiation Variants of LCIS that: carry risk for unsampled invasive cancer mimic DCIS
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationComparative Features of Ductal Carcinoma In Situ and Infiltrating Ductal Carcinoma of the Breast on Fine-Needle Aspiration Biopsy
Comparative Features of In Situ and of the Breast on Fine-Needle Aspiration Biopsy HELEN H. WANG, M.D., DR. P.H., BARBARA S. DUCATMAN, M.D., AND DAWN EICK, CT(ASCP) To evaluate the usefulness of fine-needle
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationAmerican Journal of Cancer Case Reports. Invasive Papillary Carcinoma of Male Breast: A Rare Case Report
American Journal of Cancer Case Reports http://ivyunion.org/index.php/ajccr SantraAetal. American Journal of Cancer Case Reports 2014, 3:56-61 Page 1 of 6 Vol 3 Article ID 20140617, 6 pages Case Report
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Ulamec M., Džombeta T., Čupić H., Leniček T., Tomas D., Krušlin B. (2012) Periacinar retraction clefting and d2-40 expression in prostatic adenocarcinoma. Pathology Oncology
More informationCancer cells in vitro
Supplementary Figure S1 Cancer cells in vitro Pretreatment with Control IgG (18h) Pretreatment with anti-u-par (18h) Acid Wash/Pretreatment with Control IgG (18h) Acid Wash/Pretreatment with anti-u-par
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationPapillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
More informationBenign, Reactive and Inflammatory Lesions of the Breast
Benign, Reactive and Inflammatory Lesions of the Breast Marilin Rosa, MD Associate Member Section Head of Breast Pathology Department of Anatomic Pathology Program Director, Breast Pathology Fellowship
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More information04/10/2018 HIGH RISK BREAST LESIONS. Pathology Perspectives of High Risk Breast Lesions ELEVATED RISK OF BREAST CANCER HISTORICAL PERSPECTIVES
Pathology Perspectives of High Risk Breast Lesions Savitri Krishnamurthy MD Professor of Pathology Deputy Division Head Director of Clinical Trials, Research and Development The University of Texas MD
More informationAMSER Case of the Month: November 2018
AMSER Case of the Month: November 2018 52 year old female with an abnormal screening mammogram Areeg Rehman, MS 4 Nova Southeastern University Rebecca T. Sivarajah, MD Penn State University College of
More informationIntraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationImmunohistochemical Expression Of Cytokeratin 8 And 18 In Breast Carcinoma.
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 3 Immunohistochemical Expression Of Cytokeratin 8 And 18 In Breast Carcinoma. B Rattan, A Baghla, M Manjari, P Kakkar, S Kahlon, S Paul Citation
More informationPotential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast
Potential Value of Hormone Receptor Assay in Carcinoma In Situ of Breast ROBERT BARNES, M.D. AND SHAHLA MASOOD, M.D. The estrogen receptor (ER) expression of invasive breast cancer has been extensively
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More information1 NORMAL HISTOLOGY AND METAPLASIAS
1 NORMAL HISTOLOGY AND METAPLASIAS, MD Anatomy and Histology 1 Metaplasias 2 ANATOMY AND HISTOLOGY The female breast is composed of a branching duct system, which begins at the nipple with the major lactiferous
More informationp53 expression in invasive pancreatic adenocarcinoma and precursor lesions
Malaysian J Pathol 2011; 33(2) : 89 94 ORIGINAL ARTICLE p53 expression in invasive pancreatic adenocarcinoma and precursor lesions NORFADZILAH MY MBBCH,* Jayalakshmi PAILOOR MPath, FRCPath,* RETNESWARI
More informationNeutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury
Neutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury Bastian OW, Koenderman L, Alblas J, Leenen LPH, Blokhuis TJ. Neutrophils contribute to
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCD15 and CEA expression in thymic epithelial neoplasms
Turkish Journal of Cancer Volume 8, No., 8 CD and CEA expression in thymic epithelial neoplasms AYTEKİN AKYOL, AYŞEGÜL ÜNER Hacettepe University, Department of Pathology, Ankara-Turkey ABSTRACT The aim
More informationLarge Colorectal Adenomas An Approach to Pathologic Evaluation
Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,
More informationTumour markers in breast carcinoma correlate with grade rather than with invasiveness
doi: 10.1054/ bjoc.2001.1995, available online at http://www.idealibrary.com on http://www.bjcancer.com Tumour markers in breast carcinoma correlate with grade rather than with invasiveness F Wärnberg
More informationMapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery
Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery Robert Glinert, MD and Song Q. Zhao, MD, Ph.D., MPH Department
More informationLesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct
More informationDisclosures. Premalignant Lesions of the Breast: What Clinicians Want and Why. NY Times: Prone to Error: Earliest Steps to Find Cancer.
Disclosures Premalignant Lesions of the Breast: What Clinicians Want and Why I have nothing to disclose Rick Baehner, MD Assistant Professor, UCSF Pathology NY Times: Prone to Error: Earliest Steps to
More informationAccuracy of Intraoperative Frozen-Section Analysis of Breast Cancer Lumpectomy-Bed Margins
Accuracy of Intraoperative Frozen-Section Analysis of Breast Cancer Lumpectomy-Bed Margins Juan C Cendán, MD, FACS, Dominique Coco, MD, Edward M Copeland III, MD, FACS BACKGROUND: STUDY DESIGN: RESULTS:
More informationLobular Carcinoma In Situ Variants in Breast Cores
Lobular Carcinoma In Situ Variants in Breast Cores Potential for Misdiagnosis, Upgrade Rates at Surgical Excision, and Practical Implications Megan E. Sullivan, MD; Seema A. Khan, MD; Yurdanur Sullu, MD;
More informationUse of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment
Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment Barbara L. Smith, MD, PhD Professor of Surgery, Harvard Medical School Division of Surgical Oncology Massachusetts
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More information